Ignite Creation Date:
2024-05-05 @ 7:39 PM
Last Modification Date:
2024-10-26 @ 9:52 AM
Study NCT ID:
NCT00717561
Status:
COMPLETED
Last Update Posted:
2014-11-04
First Post:
2008-07-16
Brief Title:
A Study to Assess the Efficacy and Safety of IVPO Moxifloxacin in Subjects With Community-acquired Pneumonia
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A National Prospective Randomized Open Label Study to Assess the Efficacy and Safety of IVPO Moxifloxacin vs IV Ceftriaxone IV Azithromycin Followed by PO AmoxicillineClavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone intravenous azithromycin followed by oral amoxicillineclavulanate and oral clarithromycin in the treatment of community-acquired pneumonia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007-001320-12 | EUDRACT_NUMBER | None | None |